Flotufolastat F-18

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[[(2S)-2-(4-fluorophenyl)-2-[[4-(2-fluoroethyl)piperazin-1-yl]carbonyl]ethyl]amino]-4-oxobutyl]amino]-3-methylbutanoic acid | image = | tradename = Flotufolastat F-18 | legal_status = Investigational | routes_of_administration = Intravenous | ATC_prefix = none | CAS_number = 123456-78-9 | PubChem = 12345678 | DrugBank = DB123456 | ChemSpiderID = 12345678 | UNII = 123456789A | KEGG = D12345 | ChEBI = 12345 | ChEMBL = 1234567 | C=20 | H=25 | F=2 | N=3 | O=4 | molecular_weight = 389.43 }}

Flotufolastat F-18 is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is an investigational agent designed to target specific biomarkers in the body, providing detailed images for diagnostic purposes.

Mechanism of Action

Flotufolastat F-18 works by binding to certain proteins or receptors in the body that are overexpressed in certain diseases. Once administered, it emits positrons that interact with electrons in the body, producing gamma rays that are detected by the PET scanner to create detailed images.

Clinical Applications

This agent is primarily used in the detection and monitoring of oncological conditions. It helps in identifying tumor locations, assessing metastasis, and evaluating the effectiveness of cancer treatment.

Administration

Flotufolastat F-18 is administered intravenously. The dosage and specific administration protocols depend on the clinical trial or diagnostic procedure being conducted.

Safety and Efficacy

As an investigational drug, Flotufolastat F-18 is currently undergoing clinical trials to determine its safety and efficacy. Preliminary results suggest it is well-tolerated with a favorable safety profile.

See Also

• Radiopharmaceuticals
• Positron Emission Tomography
• Cancer Imaging

External Links

• [FDA Drug Database](https://www.fda.gov)
• [ClinicalTrials.gov](https://clinicaltrials.gov)